Please login to the form below

Not currently logged in
Email:
Password:

Cancer drug, Oxaliplatin, approved for UK

Colon and rectum cancer drug, Oxaliplatin, has been approved for use in the UK

Onco Therapies Ltd (OTL), a subsidiary of Strides Arcolab, has announced that its colon and rectum cancer drug, Oxaliplatin, has been approved through a decentralised procedure for use in the UK. Approval across other European countries is expected shortly.

The drug will be manufactured at Strides' oncology complex in Bangalore, India, and used to treat advanced cancer of the colon and rectum in combination with other medicines to slow or stop cancer cell growth. It will be administered as a 5mg/ml injection.

Oxaliplatin is one of 37 drugs licensed to Pfizer on a semi-exclusive basis for sales in 17 European countries.

This is the second European approval out of 22 filings made by the OTL in 2010, for products with a combined market value of over $5bn.

15th September 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics